Pasithea Therapeutics Corp. — Investor Relations & Filings
Filings indexed
301
across all filing types
Latest filing
2024-04-06
Director's Dealing
Country
US
United States of America
Listing
US
KTTA
Pasithea Therapeutics Corp. is a clinical-stage biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders and RASopathies. The company develops new therapeutics for neurological and psychiatric conditions, with a primary focus on Neurofibromatosis type 1 (NF1), a disorder causing tumor growth along nerves, and Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease. Its research also targets Multiple Sclerosis (MS), a chronic autoimmune disease of the CNS, and schizophrenia, a disabling psychiatric illness. The company's pipeline additionally includes treatments for solid tumors.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Director's Dealing 2024 | 2024-04-06 | English | |
| Director's Dealing 2024 | 2024-04-06 | English | |
| Regulatory Filings 2024 | 2024-04-03 | English | |
| REGISTRATION STATEMENT | 2024-03-29 | English | |
| POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 | 2024-03-29 | English | |
| ANNUAL REPORT | 2024-03-29 | English |
Browse filings by year
6 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2024
15 filings
| |||||
| 13367560 | Director's Dealing 2024 | 2024-04-06 | English | ||
| 13367561 | Director's Dealing 2024 | 2024-04-06 | English | ||
| 13367562 | Regulatory Filings 2024 | 2024-04-03 | English | ||
| 13367564 | REGISTRATION STATEMENT | 2024-03-29 | English | ||
| 13367563 | POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 | 2024-03-29 | English | ||
| 13367565 | ANNUAL REPORT | 2024-03-29 | English | ||
| 13367566 | Director's Dealing 2024 | 2024-03-02 | English | ||
| 13367567 | Director's Dealing 2024 | 2024-03-02 | English | ||
| 13367568 | Director's Dealing 2024 | 2024-03-02 | English | ||
| 13367569 | Director's Dealing 2024 | 2024-03-02 | English | ||
| 13367570 | Director's Dealing 2024 | 2024-03-02 | English | ||
| 13367571 | Director's Dealing 2024 | 2024-03-02 | English | ||
| 13367572 | Director's Dealing 2024 | 2024-03-02 | English | ||
| 13367575 | CURRENT REPORT | 2024-01-18 | English | ||
| 13367573 | CURRENT REPORT | 2024-01-02 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
Pasithea Therapeutics Corp. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35389/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35389 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35389 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35389 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35389}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Pasithea Therapeutics Corp. (id: 35389)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.